In murine CRS models, dasatinib reduced mortality by lowering the levels of IFN-γ, tumor necrosis factor (TNF-α), granulocyte macrophage colony-stimulating factor (Gm-CSF), and IL-2 [79]. This evidence concerns the gene CSF2 and congenital rubella syndrome.